Search

Displaying results 7211 - 7220 of 10000 in total
  1. Drug

    Vicriviroc

    go.drugbank.com/drugs/DB06652
    Investigational

    Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. … This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells. This drug was developed by Schering-Plough.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  2. Drug

    Saredutant

    go.drugbank.com/drugs/DB06660
    Investigational

    Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.

    Categories: Heterocyclic Compounds, 1-Ring, Receptors, Neurokinin-2, antagonists & inhibitors
  3. Drug

    Odanacatib

    go.drugbank.com/drugs/DB06670
    Investigational

    Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  4. Drug

    Clazosentan

    go.drugbank.com/drugs/DB06677
    Investigational

    Categories: Receptor, Endothelin A, Heterocyclic Compounds, 1-Ring
  5. Drug

    Clevudine

    go.drugbank.com/drugs/DB06683
    Investigational

    Synonyms: 2'-Fluoro-5-methyl-beta-L-arabinofuranosyluracil, L-FMAUCategories: Heterocyclic Compounds, 1-Ring
  6. Drug

    Vilazodone

    go.drugbank.com/drugs/DB06684
    ApprovedInvestigational

    Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622].

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-Ring
  7. Drug

    Laquinimod

    go.drugbank.com/drugs/DB06685
    Investigational

    Laquinimod is an immunomodulator developed by Active Biotech and produced by Teva Pharmaceutical Industries. It is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod. I...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Ethanolamine oleate

    go.drugbank.com/drugs/DB06689
    Approved

    Ethanolamine oleate is a mild sclerosing agent. … It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, straw to pale yellow colored, deliquescent oleate.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Xylometazoline

    go.drugbank.com/drugs/DB06694
    Approved

    Xylometazoline works by binding to alpha (α)-adrenergic receptors to cause vasoconstriction of nasal blood vessels.

    Mixtures: NASOWELL 1 MG/ML+ 50 MG/ML BURUN SPREYİ, ÇÖZELTİ, 1 ADET, Ophtrivin A Ophthalmic DpsCategories: Adrenergic alpha-1 Receptor Agonists, Heterocyclic Compounds, 1-Ring
  10. Drug

    Dabigatran etexilate

    go.drugbank.com/drugs/DB06695
    ApprovedInvestigational

    Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor dabigatran. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom ...

    Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingProducts: PRADAXA® 150 MG, DABITROM® 150